Intriguingly, pharmacologic inhibition of ELAVL1 potently reduced the constitutive secretion of pro-inflammatory cytokines in skin fibroblasts from patients with type I interferonopathies and dermatomyositis, providing a new approach to treat RIG-I/cGAS-dependent interferonopathies. Here, ELAVL1 is linked to dermatomyositis.